The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | NSCLC highlights from ASCO 2021
Heather A. Wakelee, MD, Stanford University, Stanford, CA, discusses non-small cell lung cancer (NSCLC) highlights from the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, including the results of a FDA analysis, looking across metastatic NSCLC trials of patients with 1-49% PD-L1 expression; chemotherapy and immunotherapy in combination was found to be more effective than immunotherapy alone. In addition, data was presented concerning EGFR TKI osimertinib in EGFR mutated NSCLC; results were consistent with previous research, with disease-free survival (DFS) benefit but no overall survival (OS) benefit. Future research may focus on determining the optimal strategy for early-stage patients, considering screening for salient biomarkers, such as EGFR and PD-L1. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
Disclosures
Heather A. Wakelee, MD has received research funding from ACEA Biosciences, Arrys Therapeutics, AstraZeneca/Medimmune, BMS, Celgene, Clovis Oncology, Exelixis, Genentech/Roche, Gilead, Merck, Novartis, Pharmacyclics, Sea Gen, Xcovery; is on the advisory board (compensated) of AstraZeneca, Xcovery, Janssen, Daiichi Sankyo, Blueprint, Mirati, Helsinn; is on the advisory board (not compensated) of Merck Genentech/Roche; the president elect at IASLC; part of the executive committee at ECOG-ACRIN.
